|Year : 2022 | Volume
| Issue : 5 | Page : 371-376
Safety and efficacy of EUS-guided ablation of pancreatic lesions with ethanol versus ethanol with paclitaxel: A systematic review and meta-analysis
Syed Mohsin Saghir1, Banreet Singh Dhindsa2, Sarav Gunjit Singh Daid3, Yassin Naga1, Amaninder Dhaliwal4, Harmeet S Mashiana2, Neil Bhogal2, Harlan Sayles5, Daryl Ramai6, Shailender Singh2, Ishfaq Bhat2, Rajani Rangray7, Stephanie McDonough8, Douglas G Adler9
1 Department of Internal Medicine, University of Nevada Las Vegas School of Medicine, Las Vegas, Nevada, USA
2 Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA
3 Department of Internal Medicine, New York Medical College, NYC Health + Hospitals/Metropolitan, New York, NY, USA
4 Division of Gastroenterology and Hepatology, Moffitt Cancer Center, Tampa, FL, USA
5 Department of Biostatistics, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA
6 Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, New York, USA
7 Division of Gastroenterology and Hepatology, CHI Health Creighton University Medical Center, Omaha, NE, USA
8 Division of Gastroenterology and Hepatology, University of Utah, Salt Lake City, Utah, USA
9 Center for Advanced Therapeutic Endoscopy (CATE), Centura Health, Porter Hospital, Peak Gastroenterology, Denver, Colorado, USA
|Date of Submission||26-Aug-2020|
|Date of Acceptance||06-May-2021|
|Date of Web Publication||21-Sep-2021|
Dr. Douglas G Adler
Porter Adventist Hospital 2525 S Downing St, Denver, CO 80210
Source of Support: None, Conflict of Interest: None
Background and Objectives: EUS-guided ethanol ablation has emerged as an alternative method for pancreatic lesions. Recently, paclitaxel was added to ethanol to assess ablative effects in pancreatic lesions. We performed a systematic review and meta-analysis on EUS-guided ethanol ablation (EUS E) versus EUS-guided ethanol with paclitaxel (EUS EP) ablation for the management of pancreatic lesions. Methods: Comprehensive search of multiple electronic databases and conference proceedings including PubMed, EMBASE, Google Scholar, and Web of Science databases (from inception to May 2020). The primary outcome evaluated complete ablation of the lesions radiologically and the secondary outcome evaluated adverse events (AEs). Results: Fifteen studies on 524 patients were included in our analysis. The pooled complete ablation rate was 58.89% (95% confidence interval (CI) = 38.72–77.80, I2 = 91.76%) and 55.99% (95% CI = 44.66–67.05, I2 = 0) in the EUS E and EUS EP groups (P = 0.796), respectively. The pooled AE rates were 13.92% (95% CI = 4.71–26.01, I2 = 83.43%) and 31.62% (95% CI = 3.36–68.95, I2 = 87.9%) in the EUS E and EUS EP groups (P = 0.299), respectively. The most common AE was abdominal pain at 7.27% (95% CI = 1.97–14.6, I2 = 68.2%) and 12.44% (95% CI = 0.00–39.24, I2 = 81.1%) in the EUS E and EUS EP groups (P = 0.583), respectively. Correlation coefficient (r) was ‒0.719 (P = 0.008) between complete ablation and lesion size. Conclusion: Complete ablation rates were comparable among both groups. AE rates were higher in the EUS EP group. Further randomized controlled trials are needed to validate our findings.
Keywords: ethanol, lesions, meta-analysis, paclitaxel, pancreatic
|How to cite this article:|
Saghir SM, Dhindsa BS, Daid SG, Naga Y, Dhaliwal A, Mashiana HS, Bhogal N, Sayles H, Ramai D, Singh S, Bhat I, Rangray R, McDonough S, Adler DG. Safety and efficacy of EUS-guided ablation of pancreatic lesions with ethanol versus ethanol with paclitaxel: A systematic review and meta-analysis. Endosc Ultrasound 2022;11:371-6
|How to cite this URL:|
Saghir SM, Dhindsa BS, Daid SG, Naga Y, Dhaliwal A, Mashiana HS, Bhogal N, Sayles H, Ramai D, Singh S, Bhat I, Rangray R, McDonough S, Adler DG. Safety and efficacy of EUS-guided ablation of pancreatic lesions with ethanol versus ethanol with paclitaxel: A systematic review and meta-analysis. Endosc Ultrasound [serial online] 2022 [cited 2022 Nov 30];11:371-6. Available from: http://www.eusjournal.com/text.asp?2022/11/5/371/326307
| Introduction|| |
Pancreatic lesions present as a wide clinicopathologic spectrum of lesions. The many types of pancreatic lesions include, but are not limited to, serous mucinous neoplasms (SCN), mucinous cystic neoplasms (MCN), intraductal papillary mucinous neoplasms (IPMN), solid pseudopapillary neoplasms, pancreatic neuroendocrine tumors (PNET), and pancreatic fluid collections (PFC) including pseudocysts and walled off pancreatic necrosis (WON). Of primary concern is the risk of malignant transformation of pancreatic lesions. The risk of malignancy in a pancreatic cyst at the time of diagnosis is at most 0.01% or 0.21% for cysts >2 cm. EUS-FNA is an important tool in the evaluation of these lesions by means of cyst-fluid cytology and tumor-marker analysis.
In most individuals depending on the indication, surgery or surveillance may be an appropriate management for pancreatic lesions. However, surgical resection of pancreatic lesions carries significant perioperative morbidity (20%–40%) and mortality (rates as high as 2%), so there is considerable interest in minimally invasive interventions that could serve as alternatives to surgery,,, This is especially helpful in those who may be high risk for surgery or reluctant to undergo pancreatic surgery.
EUS-guided ablation with ethanol or ethanol plus paclitaxel is a minimally invasive method for the management of pancreatic lesions.,, This procedure was first described by Gan et al. in 2005. Cystic lesions in solid organs have been successfully ablated by utilizing chemical injection, with the most common injectates being ethanol and paclitaxel. Ethanol induces lysis of the cell membrane and protein denaturation, with ablative effects on the cyst epithelium. Paclitaxel exerts its effect on cystic lesions by inhibiting microtubule-dependent processes which induces cessation of cellular division followed by apoptosis. The effects are long lasting.
Studies utilizing ethanol,,, for pancreatic lesion ablation have had varying results regarding resolution (9%–80%), whereas ethanol plus paclitaxel,,, showed improved resolution (50%–79%) with long-lasting effects. However, the data on long-term outcomes are limited. Currently, this intervention has been utilized as an investigative modality on patients who refused surgery or were poor surgical candidates.
We performed a systematic review and meta-analysis comparing the safety and efficacy of EUS-guided ethanol ablation versus EUS-guided ethanol plus paclitaxel ablation of pancreatic lesions.
| Methods|| |
We performed a comprehensive search through several databases such as PubMed, EMBASE, Web of Science, and Google scholar (from inception to May 2020). A combination of keywords used in our literature search were as follows: “EUS,” “endoscopic,” “ultrasound.” “pancreatic,” “cyst,” “ablation,” “ethanol,” and “paclitaxel.” A manual search of the references section of the selected articles was also performed to find additional relevant articles. Two authors (BD and SS) carried out the search and reviewed the articles individually. A third author (YN) reviewed studies which had discrepancies for resolution. Articles that did not meet the inclusion criteria were excluded. We utilized the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines during our search for studies utilizing EUS-guided ethanol ablation versus ethanol plus paclitaxel ablation of pancreatic lesions. Refer to [Supplementary Figure 1] [Additional file 1].
Studies evaluating the clinical efficacy and adverse events (AEs) of EUS-guided ethanol ablation and ethanol with paclitaxel ablation for pancreatic lesions were reviewed. We included studies in our analysis, which reported the use of ethanol or ethanol plus paclitaxel for the management of pancreatic lesions as long as they had data to be extracted and did not fulfill criteria for exclusion. All of our patients were over 18 years and were included regardless of the number of lesions or loculations. We also included studies reporting outcomes on any type of pancreatic lesion irrespective of whether it was suspected to be benign, indeterminate, or malignant, and regardless of symptoms. The following exclusion criteria were used (1) studies utilizing other methods to ablate a pancreatic cyst, (2) ages <18 years old or prisoners, (3) studies not in the English language, and (4) studies with <10 patients. In the event of cohort overlap, the most appropriate study was selected, and the other was excluded.
Data abstraction and quality assessment
Quality assessment of the studies was performed independently by two authors (BD and SS). Any differences were discussed with a third author (YN) to reach a consensus between the authors. The Newcastle–Ottawa scale was used to assess the quality of the cohort studies. Quality assessment for randomized controlled trials was done with the Jadad–Oxford scale.
The primary outcome was the complete ablation success rate of pancreatic lesions with either ethanol or ethanol plus paclitaxel.
The secondary outcomes of the study included overall AE and adverse event subtypes.
In most studies, response to treatment was assessed by comparing the original lesion volume to post treatment lesion volume by either EUS, computed tomography or magnetic resonance imaging. The response was interpreted as complete resolution, which was defined as either no visualization of the lesion or at least ≥95% reduction of lesion volume on follow-up imaging.
We utilized the meta-analysis technique suggested by DerSimonian and Laird to calculate the pooled estimates for each outcome of interest by following the random effects model. If a value of zero occurred in the outcome of a study, then a value of 0.5 was added before statistical analysis. The Cochran Q statistical test and I2 statistics were utilized to assess heterogeneity., Heterogeneity was classified by the values of <30%, 30%–60%, 61%–75%, and >75%, which suggest low, moderate, substantial, and considerable heterogeneity, respectively. We utilized the Pearson correlation coefficient (r) to investigate potential association of pancreatic lesion size with complete ablation. All analyses were performed using STATA v16.1 software (StataCorp, LLC College Station, TX).
| Results|| |
Search results and population characteristics
Fifteen studies from an initial pool of 598 studies reporting data on EUS-guided ethanol (EUS E) ablation and EUS-guided E + P ablation (EUS EP) were included in our final analysis.,,,,,,,,,,,,,, The final meta-analysis included 14 cohort studies and 1 randomized controlled trial. Twelve studies were prospective and three were retrospective. Thirteen studies were single center and two were multi-center. No studies were population based. The quality assessment of the studies can be viewed in [Supplementary Table 1] [Additional file 2].
The EUS E group included 142 males (35%) and 265 females (65%). The EUS EP group included 30 males (36%) and 54 females (64%). The mean age in years was 59.3 and 57 in the EUS E and EUS EP groups, respectively. The location of the lesion was reported in 10 of the 11 studies in the EUS E group and 3 of the 4 studies in the EUS EP group. The most common lesion location in the EUS E group was the head/uncinate process (43%) followed by the body (32%), then the tail (25%) of the pancreas. The most common lesion location in the EUS EP group was the tail (52%) followed by the head/uncinate process (34%), then body (13%) of the pancreas. The mean follow-up period in months for the EUS E versus EUS EP groups was 28.3 and 18.2, respectively. [Table 1] outlines the characteristics of the included studies.
The pooled complete ablation rate was 58.89% (95% CI = 38.72-77.80, I2 = 91.76%) and 55.99% (95% CI = 44.66-67.05, I2 = 0) in the EUS E and EUS EP groups (P = 0.796), respectively. [Figure 1] displays the forest plots for the complete ablation rates for EUS E and EUS EP.
|Figure 1. Displays the forest plots for the complete ablation rates for ethanol and ethanol with paclitaxel|
Click here to view
The pooled overall adverse event (AE) rates were 13.92% (95% confidence interval (CI) = 4.71–26.01, I2 = 83.43%) and 31.62% (95% CI = 3.36–68.95, I2 = 87.9%) in the EUS E and EUS EP groups (P = 0.299), respectively. The most common AE was abdominal pain at 7.27% (95% CI = 1.97–14.6, I2 = 68.2%) and 12.44% (95% CI = 0.00–39.24, I2 = 81.1%) in the EUS E and EUS EP groups (P = 0.583), respectively. Postprocedure pancreatitis was the next most common AE at 3.14% (95% CI = 0.60–6.91, I2 = 33.01%) and 3.78% (95% CI = 0.00–15.32, I2 = 47.84%) in the EUS E and EUS EP groups (P = 0.769), respectively. The correlation coefficient (r) was ‒0.719 (P = 0.008) between complete ablation and pancreatic lesion size. AEs are detailed in [Table 2].
Validation of meta-analysis results
One study at a time was excluded to evaluate its effect on the main outcome and we found that no single study had a significant effect on the main outcome or the heterogeneity.
Utilizing the Q statistics and I2 analysis for heterogeneity, considerable heterogeneity was noted in the EUS E group and low heterogeneity was noted in the EUS EP group for the primary outcome. Considerable heterogeneity was noted in the overall AE for both groups. Considerable heterogeneity was noted in the EUS EP group and substantial heterogeneity in the EUS E group for abdominal pain. Moderate heterogeneity was noted in postprocedural pancreatitis for both groups.
It was difficult to estimate publication bias since we are evaluating small, one arm studies with dichotomous outcomes.
| Discussion|| |
To our knowledge, this is the first meta-analysis comparing the outcomes of EUS E versus EUS EP ablation for pancreatic lesions. Our study demonstrated that, in patients with pancreatic lesions undergoing EUS E ablation or EUS EP ablation, the rates of complete ablation were comparable.
Based on our analysis, the pooled complete ablation rates were comparable between the EUS E and EUS EP groups at 58.89% versus 55.99%, respectively. Complete ablation rates in the EUS E and EUS EP groups ranged from 8.7% to 100% and 45%–75%, respectively. In the EUS E group, studies which conducted treatments on PNET had greater complete ablation rates as compared to those involving other types of pancreatic lesions (MCN, SCN, IPMN, PFC, and WON).,,,, However, there were no PNETs treated in the EUS EP group and the complete ablation success rate was not limited to any specific types of lesions. Furthermore, it was reported that unilocularity was a contributing factor to complete ablation rates as injection of a therapeutic agent into the cyst could reach the entire lining, without being blocked by septations, but several studies from our meta-analysis had varying results regarding this.,,,,
The pooled AE rates were greater in the EUS EP group as compared to the EUS E group at 31.62% versus 13.92%, respectively. This finding was not statistically significant (P = 0.299) and is likely underpowered due to the smaller number of patients in the EUS EP group as compared to the EUS E group (88 vs. 436), respectively. Abdominal pain was the most common AE followed by postprocedural pancreatitis in the EUS E and EUS EP groups with comparable rates at 7.27% vs 12.44% and 3.14% versus 3.78%, respectively. One study from the EUS E group had the most cases of post procedural pancreatitis (21) and the risk for pancreatitis was attributed to having multilocular cysts, sticky cystic fluid, or ethanol leakage from the pancreatic lesion. In the study by Park et al., pancreatitis risk increased when more than 2 ml of ethanol was utilized for lavage.
There was a strong negative correlation between complete ablation rates and pancreatic lesion size with an r value of ‒0.719 (P = 0.008). This makes intuitive sense and suggests that complete ablation is more likely when pancreatic lesions are small. One study in the EUS EP group reported a cyst size <35 mm to be predictive of complete ablation and 2 studies in the EUS E group reported cyst sizes <27 mm to be predictive of complete ablation.,,
This study has several limitations. The study population was small in the EUS EP group. There was substantial to considerable heterogeneity. There is a paucity of randomized controlled trials. Varying doses of the ablative agents were utilized, since there are no current guidelines to follow. There were not enough resected specimens to study the effects of what ablative agents do to pancreatic lesions. The average follow-up period was lower in the EUS EP group at 18.2 months as compared to 28.3 months in the EUS E group. Longer follow up periods should be pursued in future studies to assess long-term effects of chemical ablation despite resolution of cysts on initial follow-up. Furthermore, the longer follow-up will allow for assessment of mucinous cysts as degeneration may take up to 5–10 years.,,
In summary, this study showed comparable rates of complete ablation between the EUS E and EUS EP groups. There was a strong negative correlation between complete ablation rates and smaller lesion sizes. The overall AE rates were found to be greater in the EUS EP group, but the rates of abdominal pain and postprocedural pancreatitis were comparable between both groups. Future studies should evaluate paclitaxel's effect alone on pancreatic lesions to assess any advantage from a safety and efficacy standpoint. Further randomized control trials are needed to validate our findings.
Supplementary information is linked to the online version of the paper on the Endoscopic Ultrasound website.
Financial support and sponsorship
Conflicts of interest
Douglas G. Adler is a Co-Editor-in-Chief of the journal. The article was subject to the journal's standard procedures, with peer review handled independently of this Editor and his research groups.
| References|| |
DeWitt J, McGreevy K, Schmidt CM, et al
. EUS-guided ethanol versus saline solution lavage for pancreatic cysts: A randomized, double-blind study. Gastrointest Endosc
Hamilton SR, Aaltonen LA. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press; 2000.
Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology
Ahmad NA, Kochman ML, Lewis JD, et al
. Can EUS alone differentiate between malignant and benign cystic lesions of the pancreas? Am J Gastroenterol
Elta GH, Enestvedt BK, Sauer BG, et al
. ACG clinical guideline: Diagnosis and management of pancreatic cysts. Am J Gastroenterol
Goh BK, Tan YM, Cheow PC, et al
. Cystic lesions of the pancreas: an appraisal of an aggressive resectional policy adopted at a single institution during 15 years. Am J Surg
Horvath KD, Chabot JA. An aggressive resectional approach to cystic neoplasms of the pancreas. Am J Surg
Attila T, Adsay V, Faigel DO. The efficacy and safety of endoscopic ultrasound-guided ablation of pancreatic cysts with alcohol and paclitaxel: A systematic review. Eur J Gastroenterol Hepatol
Cho MK, Choi JH, Seo DW. Endoscopic ultrasound-guided ablation therapy for pancreatic cysts. Endosc Ultrasound
Oh HC, Seo DW, Song TJ, et al
. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts. Gastroenterology
DeWitt JM, Al-Haddad M, Sherman S, et al
. Alterations in cyst fluid genetics following endoscopic ultrasound-guided pancreatic cyst ablation with ethanol and paclitaxel. Endoscopy
Gan SI, Thompson CC, Lauwers GY, et al
. Ethanol lavage of pancreatic cystic lesions: Initial pilot study. Gastrointest Endosc
Gelczer RK, Charboneau JW, Hussain S, et al
. Complications of percutaneous ethanol ablation. J Ultrasound Med
DiMaio CJ, DeWitt JM, Brugge WR. Ablation of pancreatic cystic lesions: The use of multiple endoscopic ultrasound-guided ethanol lavage sessions. Pancreas
Caillol F, Poincloux L, Bories E, et al
. Ethanol lavage of 14 mucinous cysts of the pancreas: A retrospective study in two tertiary centers. Endosc Ultrasound
Gómez V, Takahashi N, Levy MJ, et al
. EUS-guided ethanol lavage does not reliably ablate pancreatic cystic neoplasms (with video). Gastrointest Endosc
Oh HC, Seo DW, Lee TY, et al
. New treatment for cystic tumors of the pancreas: EUS-guided ethanol lavage with paclitaxel injection. Gastrointest Endosc
Oh HC, Seo DW, Kim SC, et al
. Septated cystic tumors of the pancreas: Is it possible to treat them by endoscopic ultrasonography-guided intervention? Scand J Gastroenterol
Kim KH, McGreevy K, La Fortune K, et al
. Sonographic and cyst fluid cytologic changes after EUS-guided pancreatic cyst ablation. Gastrointest Endosc
Canakis A, Law R, Baron T. An updated review on ablative treatment of pancreatic cystic lesions. Gastrointest Endosc
Moher D, Liberati A, Tetzlaff J, et al
. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol
Jadad AR, Moore RA, Carroll D, et al
. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials
Sutton AJ, Abrams KR, Jones DR, et al
. Methods for Meta-Analysis in Medical Research. Chichester: Wiley; 2000.
Higgins JP, Thompson SG, Deeks JJ, et al
. Measuring inconsistency in meta-analyses. BMJ
Kanwal F, White D. “Systematic reviews and meta-analyses” in clinical gastroenterology and hepatology. Clin Gastroenterol Hepatol
Guyatt GH, Oxman AD, Kunz R, et al
. GRADE guidelines: 7. Rating the quality of evidence – Inconsistency. J Clin Epidemiol
Choi JH, Lee SH, Choi YH, et al
. Safety of endoscopic ultrasound-guided ethanol ablation for pancreatic cystic lesions: A single-center experience of 214 patients. Hepatobiliary Pancreat Dis Int
Levy MJ, Thompson GB, Topazian MD, et al
. US-guided ethanol ablation of insulinomas: A new treatment option. Gastrointest Endosc
Matsumoto K, Kato H, Kawano S, et al
. Efficacy and safety of scheduled early endoscopic ultrasonography-guided ethanol reinjection for patients with pancreatic neuroendocrine tumors: Prospective pilot study. Dig Endosc
Paik WH, Seo DW, Dhir V, et al
. Safety and efficacy of EUS-guided ethanol ablation for treating small solid pancreatic neoplasm. Medicine (Baltimore)
Song BJ, Paik WH, Kim J, et al
. 279 outcome of endoscopic ultrasonography-guided ethanol lavage for incidental pancreatic cysts. Gastrointest Endosc
Park JK, Song BJ, Ryu JK, et al
. Clinical outcomes of endoscopic ultrasonography-guided pancreatic cyst ablation. Pancreas
Park DH, Choi JH, Oh D, et al
. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: Results of a pilot study. Clin Endosc
Qin S, Jiang H, Luo W. Su1380 efficacy of EUS-guided ethanol injection in the treatment of benign and symptomatic insulinomas. Gastroenterology
Oh HC, Seo DW, Kim SH, et al
. Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. Dig Dis Sci
Moyer MT, Dye CE, Sharzehi S, et al
. Is alcohol required for effective pancreatic cyst ablation? The prospective randomized CHARM trial pilot study. Endosc Int Open
Zamboni G, Scarpa A, Bogina G, et al
. Mucinous cystic tumors of the pancreas: Clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol
[Table 1], [Table 2]